Department of Breast Cancer,Cancer Hospital

Guangdong Provincial People'sHospital

Guangdong Academy of MedicalSciences

Member of Guangdong TranslationalMedical Association

Member of CSCO

Member of ASCO

2015 ESMO-ASIA Travel Award Winner，2016 ELCC Travel Award Winner，2016 APLCC Travel Award Winner，2016 ESMO-ASIA Travel Award Winner

Specializing in themultidisciplinary treatment of breast cancer, molecular markers to predict theefficacy of neoadjuvant therapy for breast cancer and the mechanism of drug resistance.

Education

2004.9-2009.6 Southern Medical University，Bachelor degree

2009.9-2012.6 Sun Yat-Senuniversity，Master degree

2013.9-2016.6 Guangdong Lung Cancer Institute, Guangdong ProvincialPeople's Hospital & Guangdong Academy of Medical Science，Doctor degree

Publications

1. Gao, HF; Wu, Z; Lin, Y; Wang, K;et al. Anthracycline-containing versus carboplatin-containing neoadjuvant chemotherapy in combination with trastuzumab for HER2-positive breast cancer: the neoCARH phase II randomized clinical trial. Ther Adv Med Oncol.2021 ;13:17588359211009003.

2. Li, WP; Gao, HF; Ji, F; Wang, K, et al. The role of adjuvant chemotherapy in stage I–III male breastcancer: a SEER-based analysis. Ther Adv Med Oncol.2020 ;12:1758835920958358.

3. Gao, HF; Li, WP; Zhu, T; Wang, K, et al. Adjuvant chemotherapy could benefit early-stage ER/PR positivemucinous breast cancer: A SEER-based analysis. Breast.2020 Dec ;54:79-87.

4.Gao, HF; Yang, CQ; Cheng, MY; Wang, K; et al. Prognostic Significance of Mesenchymal-Epithelial Transitionin Triple-Negative Breast Cancers. Clin Breast Cancer.2018 10 ;18(5):e961-e966.

5. Li AN, Yang JJ, Zhang XC, Zhang ZH, Su J, Gou LY, Bai Y, Zhou Q,Yang ZH, Zhang HH, Zhong WZH, Chuai S, Xie ZH, Zhang Q, Gao HF, Chen HJ, WangZH, Wang BC, Xu CR, Liu SY, Wu SP, Jiang BY, Chen ZHH, Gan B, Wang ZH, Yang XN,Wu YL. Acquired MET Y1248H and D1246N Mutations Mediate Resistance to METInhibitors in Non–Small Cell Lung Cancer. Clin Cancer Res.2017 Aug 15 ;23(16):4929-4937

6. Gao HF, Li AN, Yang JJ, Chen ZH, Xie Z, Zhang XC, Su J, Lou NN, Yan HH, Han JF, Wu YL. Soluble c-Met Levels Correlated With Tissue c-Met Protein Expression in Patients With AdvancedNon-Small-Cell Lung Cancer. Clin Lung Cancer.2017 01 ;18(1):85-91.                 7. 7. Liu SY, Gou LY, Li AN, Lou NN, Gao HF, Su J, Yang JJ, Zhang XC, Shao Y, Dong ZY, Zhou Q, Zhong WZ, Wu YL. The Unique Characteristics of MET Exon 14 Mutation inChinese Patients with NSCLC. J Thorac Oncol. 2016 Sep;11(9):1503-10.

8. Li, A; Gao, HF; Wu, YL.Targeting the MET pathway for potential treatment of NSCLC. Expert Opin Ther Targets.2015 May ;19(5):663-74.

9. Gao, HF; Liang, Y; Zhou, NN; Wu, HY. Aprepitant plus palonosetron and dexamethasone for prevention ofchemotherapy-induced nausea and vomiting in patients receiving multiple-daycisplatin chemotherapy. Intern Med J.2013 Jan ;43(1):73-6.